Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

1 Apr 2023

Abstract excerpt

BACKGROUND: Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug. In our previous study, we found that human menstrual blood-derived stem cells (MenSCs) altered the expression of some sorafenib resistance-associated genes in HCC cells....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cancer Cells and Metastasis
Share to Cancer Mechanisms and Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37005657
DOI: 10.1186/s13287-023-03278-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagyPMID 37005657Read ↗

Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elementsSemantic proximity Read ↗

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Cancer stem cell-mediated therapeutic resistance in hepatocellular carcinomaSemantic proximity Read ↗

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma CellsSemantic proximity Read ↗

Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinomaSemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.Semantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic toolsSemantic proximity Read ↗

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signalingSemantic proximity Read ↗

MicroRNA-140-5p Suppresses The PD-L1 Level In Exosomes Derived From Hepatocellular Carcinoma Cells, Thereby Attenuating The Chemoresistance, Autophagy And Stemness Induced By Sorafenib In Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.